These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38969304)

  • 21. Prognostic Significance of HER2 Expression in Patients with Bacillus Calmette-Guérin-exposed Non-muscle-invasive Bladder Cancer.
    Tan X; Liu Z; Cai T; Wang Y; Wu Z; Qin Z; Li Z; Liu Z; Yuan G; Zhou Q; Yao K
    Eur Urol Oncol; 2024 Aug; 7(4):760-769. PubMed ID: 37884420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective descriptive 1-year study in France of all BCG therapy dispensations for non-muscle-invasive bladder cancer.
    Neuzillet Y; Leon P; Seisen T; Allory Y; Audenet F; Loriot Y; Masson-Lecomte A; Mejean A; Pradère B; Roumiguié M; Traxer O; Xylinas E; Fournier G; Roupret M
    BJU Int; 2023 May; 131(5):611-616. PubMed ID: 36462164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Natural History of Multiple Recurrences in Intermediate-Risk Non-Muscle Invasive Bladder Cancer: Lessons From a Prospective Cohort.
    Sharma V; Chamie K; Schoenberg M; Lee VS; Fero K; Lec P; Munneke JR; Aaronson DS; Kushi LH; Quesenberry CP; Tang L; Kwan ML
    Urology; 2023 Mar; 173():134-141. PubMed ID: 36574911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utility of the EORTC risk tables and CUETO scoring model for predicting recurrence and progression in non-muscle-invasive bladder cancer patients treated with routine second transurethral resection.
    Zhang G; Steinbach D; Grimm MO; Horstmann M
    World J Urol; 2019 Dec; 37(12):2699-2705. PubMed ID: 30911812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
    Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
    J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravesical gemcitabine for non-muscle invasive bladder cancer.
    Han MA; Maisch P; Jung JH; Hwang JE; Narayan V; Cleves A; Hwang EC; Dahm P
    Cochrane Database Syst Rev; 2021 Jun; 6(6):CD009294. PubMed ID: 34125951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy.
    van Rhijn BW; Burger M; Lotan Y; Solsona E; Stief CG; Sylvester RJ; Witjes JA; Zlotta AR
    Eur Urol; 2009 Sep; 56(3):430-42. PubMed ID: 19576682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC).
    Nicklas AP; Kramer MW; Serth J; Hennenlotter J; Hupe MC; Reimer DU; Stenzl A; Merseburger AS; Kuczyk MA; von Klot CJ
    Adv Ther; 2018 Nov; 35(11):2054-2068. PubMed ID: 30232708
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update.
    Babjuk M; Oosterlinck W; Sylvester R; Kaasinen E; Böhle A; Palou-Redorta J; Rouprêt M;
    Eur Urol; 2011 Jun; 59(6):997-1008. PubMed ID: 21458150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
    Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
    BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer.
    Chen JX; Huang WT; Zhang QY; Deng CE; Wei JL; Xie YL; Lin R; Feng GZ; Yang GL; Long J; Lu HY; Mo ZN
    BMC Cancer; 2023 Oct; 23(1):1018. PubMed ID: 37872516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).
    Babjuk M; Burger M; Capoun O; Cohen D; Compérat EM; Dominguez Escrig JL; Gontero P; Liedberg F; Masson-Lecomte A; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Seisen T; Soukup V; Sylvester RJ
    Eur Urol; 2022 Jan; 81(1):75-94. PubMed ID: 34511303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
    Babjuk M; Burger M; Zigeuner R; Shariat SF; van Rhijn BW; Compérat E; Sylvester RJ; Kaasinen E; Böhle A; Palou Redorta J; Rouprêt M;
    Eur Urol; 2013 Oct; 64(4):639-53. PubMed ID: 23827737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and Validation of a Novel Recurrence Risk Stratification for Initial Non-muscle Invasive Bladder Cancer in Asia.
    Ieda T; Muto S; Shimizu F; Taguri M; Yanada S; Kitamura K; Terai K; Saito K; Ogishima T; Nagata M; Ide H; Okegawa T; Wakumoto Y; Sakamoto Y; Tsujimura A; Yamaguchi R; Nutahara K; Horie S
    EBioMedicine; 2016 Oct; 12():98-104. PubMed ID: 27614395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Presence of Concomitant Non-muscle-invasive Bladder Cancer in Chinese Patients with Upper Tract Urothelial Carcinoma: Risk Factors, Characteristics, and Predictive Value.
    Fang D; Zhang L; Li X; Yu W; Singla N; Zhao G; Xiong G; Song Y; He Q; He Z; Zhou L
    Ann Surg Oncol; 2015 Aug; 22(8):2789-98. PubMed ID: 25564161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Local recurrence and progression of non-muscle-invasive bladder cancer in Sweden: a population-based follow-up study.
    Liedberg F; Hagberg O; Holmäng S; Hosseini Aliabad A; Jancke G; Ljungberg B; Malmström PU; Åberg H; Jahnson S
    Scand J Urol; 2015; 49(4):290-5. PubMed ID: 25624049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The association between BCG treatment in patients with bladder cancer and subsequent risk of developing Alzheimer and other dementia.-A Swedish nationwide cohort study from 1997 to 2019.
    Wang E; Hagberg O; Malmström PU
    PLoS One; 2023; 18(12):e0292174. PubMed ID: 38096211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of tumor size on the oncological outcome of high-grade nonmuscle invasive bladder cancer - examining the utility of classifying Ta bladder cancer based on size.
    Tully KH; Moschini M; von Rundstedt FE; Aziz A; Kluth LA; Necchi A; Rink M; Hendricksen K; Sargos P; Vetterlein MW; Seiler R; Poyet C; Krajewski W; Fajkovic H; Shariat SF; Xylinas E; Roghmann F
    Urol Oncol; 2020 Nov; 38(11):851.e19-851.e25. PubMed ID: 32739227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic DNA Methylation Biomarkers in High-risk Non-muscle-invasive Bladder Cancer: A Systematic Review to Identify Loci for Prospective Validation.
    Gurung PMS; Barnett AR; Wilson JS; Hudson J; Ward DG; Messing EM; Bryan RT
    Eur Urol Focus; 2020 Jul; 6(4):683-697. PubMed ID: 30803927
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Refraining from Smoking for 15 Years or More Reduced the Risk of Tumor Recurrence in Non-muscle Invasive Bladder Cancer Patients.
    Ogihara K; Kikuchi E; Yuge K; Ito Y; Tanaka N; Matsumoto K; Miyajima A; Asakura H; Oya M
    Ann Surg Oncol; 2016 May; 23(5):1752-9. PubMed ID: 26671037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.